Rifampin and Rifabutin drug interactions - An update

被引:165
作者
Finch, CK
Chrisman, CR
Baciewicz, AM
Self, TH
机构
[1] Univ Tennessee, Dept Clin Pharm, Memphis, TN 38163 USA
[2] Secure Pharm, Franklin, TN USA
[3] Univ Hosp Cleveland, Dept Pharm Serv, Cleveland, OH USA
关键词
D O I
10.1001/archinte.162.9.985
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes. A few examples of well-documented clinically significant interactions include interactions with warfarin, oral contraceptives, cyclosporine, glucocorticoids, ketoconazole or intraconazole, theophylline, quinidine sulfate, digitoxin or digoxin, verapamil hydrochloride, human immunodeficiency virus-related protease inhibitors, zidovudine, delavirdine mesylate, nifedipine, and midazolam. Recent reports have demonstrated clinically relevant interactions with numerous other drugs, such as buspirone hydrochloride, zolpidem tartrate, simvastatin, propafenone hydrochloride, tacrolimus, ondansetron hydrochloride, and opiates. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Enhanced knowledge of known interactions will continue to develop, including research on the induction of specific cytochrome P-450 isoenzymes and on the importance of the P-glycoprotein transport system. New rifampin and rifabutin interactions will be discovered with further investigations.
引用
收藏
页码:985 / 992
页数:8
相关论文
共 56 条
[1]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[2]  
Apseloff G, 1998, J CLIN PHARMACOL, V38, P830
[3]   RIFAMPIN DRUG-INTERACTIONS [J].
BACIEWICZ, AM ;
SELF, TH .
ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (08) :1667-1671
[4]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS [J].
BACIEWICZ, AM ;
SELF, TH ;
BEKEMEYER, WB .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (03) :565-568
[5]   The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin [J].
Backman, JT ;
Kivistö, KT ;
Olkkola, KT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) :53-58
[6]   The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive [J].
Barditch-Crovo, P ;
Trapnell, CB ;
Ette, E ;
Zacur, HA ;
Coresh, J ;
Rocco, LE ;
Hendrix, CW ;
Flexner, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (04) :428-438
[7]   The clinical pharmacokinetics of rifabutin [J].
Blaschke, TF ;
Skinner, MH .
CLINICAL INFECTIOUS DISEASES, 1996, 22 :S15-S21
[8]   UPDATE ON RIFAMPIN DRUG-INTERACTIONS .2. [J].
BORCHERDING, SM ;
BACIEWICZ, AM ;
SELF, TH .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (04) :711-716
[9]   Pharmacogenetics of the human drug-transporter gene MDR1:: impact of polymorphisms on pharmacotherapy [J].
Brinkmann, U ;
Roots, I ;
Eichelbaum, M .
DRUG DISCOVERY TODAY, 2001, 6 (16) :835-839
[10]  
Caraco Y, 2000, CLIN PHARMACOL THER, V67, P98